Absolute oral bioavailability of milvexian spray‐dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach

Abstract

Abstract Milvexian is an oral, small‐molecule factor XIa inhibitor being developed to prevent thromboembolic events. This study assessed the absolute bioavailability (F) of milvexian following single doses of milvexian spray‐dried dispersion (SDD) formulation under fed and fasted conditions, and milvexian solution, in healthy adult participants using an intravenous microtracer approach. This was a phase I, open‐label, partially randomized, 4‐sequence, 5‐period crossover study. After fasting for ≥10 h, participants received milvexian 200‐mg oral solution with a 100‐μg 14C milvexian intravenous microtracer at the time of maximum observed plasma concentration. Following a 3‐day washout, participants were randomized to 1 of 4 milvexian SDD treatment sequences in a crossover fashion: 25 mg fasted, 25 mg fed, 200 mg fasted, or 200 mg fed. Pharmacokinetic data were collected up to 72 h postdose. Seventeen participants were dosed, and 14 completed treatment. Under fasted conditions, milvexian F was ~100%, 58.2%, and 54.2% following administration of the oral solution, 25 mg SDD, and 200 mg SDD, respectively. Under fed conditions, milvexian F following 25 mg and 200 mg SDD was 44.3% and 75.6%, respectively. The milvexian SDD formulation at 25 mg and 200 mg resulted in similar F in a fasted state; under fed conditions, milvexian F decreased at 25 mg and increased at 200 mg. These findings clarify pharmacokinetic‐related gaps observed in previous studies.